Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule
MT newswire2026/10/07 17:4301:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tessera Defense and Homeland Security announces special shareholder meeting
Tessera Defense and Homeland Security will hold a special shareholder meeting in Netanya, Israel on Oct. 20, 2026. Votes will cover an amendment to the 2026 Equity Incentive Plan to increase shares available for equity awards. The proposal would support equity grants tied to CEO Michael Oster’s employment agreement, including stock options, RSUs, and fully vested shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tessera Defense and Homeland Security Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071430PRIMZONEFULLFEED9841604) on October 07, 2026, and is solely responsible for the information contained therein.
Corteva Shares Rise After Upgrade From KeyBanc
02:22 PM EDT, 10/07/2026 (MT Newswires) -- Corteva (CTVA) shares were up 3.9% in afternoon trading on Wednesday after KeyBanc upgraded the company's stock to overweight from sector-weight. Trading volume exceeded 20.1 million shares against a daily average of roughly 10.4 million. Price: 14.45, Change: +0.54, Percent Change: +3.88
Federal Reserve officials: Not enough progress seen in reducing inflation
Data: ETH Falls Below $2550